Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 4:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2497–2520 of 17,766 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Population Clear all

Conditions: Aggression
Interventions: Videos, Bumper stickers, Alcohol-related cues, Music, Roadside vegetation, Video game; Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2025
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Painful Diabetic Neuropathies
Interventions: Low Dose: 16 mg Engensis (VM202), High Dose: 32 mg Engensis (VM202), Control- Placebo (normal saline); Biological · Other
Lead sponsor: Helixmith Co., Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 13
States / cities: Walnut Creek, California • Orlando, Florida • Palm Beach Gardens, Florida + 9 more

Conditions: Asthma
Interventions: IPL512,602 20 mg once daily, IPL512,602 Matching Placebo once daily; Drug
Lead sponsor: Inflazyme Pharmaceuticals Ltd; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 8
States / cities: Long Beach, California • Los Angeles, California • San Diego, California + 5 more

Conditions: Schizophrenia
Interventions: SEP-363856 50mg, SEP-363856 75mg, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 13 Years to 65 Years
Enrollment: 463 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 18
States / cities: Little Rock, Arkansas • Anaheim, California • Bellflower, California + 13 more

Conditions: Diabetes, Diabetes Mellitus, Glucose, High Blood, Glucose, Low Blood
Interventions: Dexcom Generation 6 CGM (Dexcom Gen6) device; Device
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Temple, Texas

Conditions: Narcolepsy, Excessive Daytime Sleepiness, Cataplexy Narcolepsy
Interventions: mazindol extended release, Placebo; Drug
Lead sponsor: NLS Pharmaceutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 22
States / cities: Birmingham, Alabama • Redwood City, California • San Diego, California + 17 more

Conditions: Stroke, Stroke, Acute, Stroke, Ischemic
Interventions: AER-271, Placebo; Drug
Lead sponsor: Aeromics, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Parkinson's Disease
Interventions: LUBIPROSTONE; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 85 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Tampa, Florida • Houston, Texas

Conditions: COVID-19
Interventions: COVID-19 Test Reporting, Personalized Nudges via Text Messaging, Non-personalized Nudges via Text Messaging; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 290 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Diabetic Macular Edema
Interventions: Faricimab, Ranibizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 60
States / cities: Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 53 more

Conditions: Subarachnoid Hemorrhage, Aneurysmal, Headache, Opiate Dependence, Opioid Use
Interventions: Lidocaine, Lidocaine and Dexamethasone; Drug
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 100 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Congenital Heart Disease
Interventions: transfusion strategy, Low Hb transfusion group; Other
Lead sponsor: University of Rochester; Other
Eligibility: 4 Months to 7 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Emotion, Impaired Cognition
Interventions: Music, Imagery, Movement, Social Control; Behavioral
Lead sponsor: George Mason University; Other
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Manassas, Virginia

Conditions: Multiple Chronic Conditions, Patient Engagement, Burnout, Professional, Motivational Interviewing, Implicit Bias
Interventions: Basic AI (artificial intelligence)-Augmented Motivational Interviewing Training, Plus AI (artificial intelligence)-Augmented Motivational Interviewing Training; Behavioral
Lead sponsor: Wright State University; Other
Eligibility: 21 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Dayton, Ohio

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: TD-4208, Placebo; Drug
Lead sponsor: Mylan Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 619 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Severe Asthma
Interventions: Tezepelumab, Budesonide/formoterol, Albuterol/budesonide (AIRSUPRA®), Mannitol, Salbutamol; Combination Product
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 8
States / cities: Palmdale, California • Colorado Springs, Colorado • Miami, Florida + 5 more

Conditions: Tourette Syndrome
Interventions: NBI-98854, Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 44
States / cities: Sun City, Arizona • Springdale, Arkansas • Long Beach, California + 41 more

Conditions: Mechanical Low Back Pain
Interventions: Patient Decision Making tool, Standard of care; Behavioral · Other
Lead sponsor: Walsh University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Premature Ejaculation
Interventions: IX-01, Placebo; Drug
Lead sponsor: Ixchelsis Limited; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 8
States / cities: San Diego, California • Aventura, Florida • West Palm Beach, Florida + 5 more

Conditions: Medication Adherence, Glaucoma
Interventions: Devers Drop Device (D3) app; Device
Lead sponsor: Universal Adherence LLC; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Behavior
Interventions: Recidivism Reduction Program, Business-as-usual; Behavioral
Lead sponsor: Pepperdine University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 4
States / cities: Grants, New Mexico • Los Lunas, New Mexico • Santa Fe, New Mexico + 1 more

Conditions: Diabetes, Glycinemia
Interventions: Usual standard of care, Neuropsychological Consultation; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 10 Years to 18 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Effect of Drug
Interventions: Bupivacaine Injection; Drug
Lead sponsor: State University of New York - Upstate Medical University; Other
Eligibility: Up to 89 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Alcohol Abuse, Criminal Behavior
Interventions: Mindfulness, Relapse Prevention; Behavioral
Lead sponsor: The Mind Research Network; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 392 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Search by objective public record fields.

Aggressive Driving and Road Rage: A Driving Simulation Experiment.

Safety and Efficacy Study for the Treatment of Painful Diabetic Neuropathy

Control of Asthma Patients Symptomatic on Inhaled Corticosteroids

A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia

Continuous Glucose Monitoring of Hospitalized Patients With Diabetes

Four-week Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in the Treatment of Narcolepsy

Phase 1 Study to Assess AER-271

Amitiza in Constipation Associated With PD (Parkinson's Disease)

Promoting Engagement and COVID-19 Testing for Health

A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema

Infusion of Lidocaine and Steroids in Middle Meningeal Artery for Pain in Subarachnoid Hemorrhage

Transfusion Strategies in Pediatric Cardiothoracic Surgery

Examining the Effects of (MiM) Treatment on Emotional and Cognitive Functioning of Residents in Long-term Care

AI-Augmented Motivational Interviewing Training for Primary Care

Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)

Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome

Influence of Patient-Informed Choice in a Novel Treatment Model for LBP

IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT) and Patient Reported Outcomes in Men With Premature Ejaculation (PE)

A Universal Eye Drop Adherence Monitor to Measure and Improve Adherence to Ocular Medications

Evaluating New Mexico's Recidivism Reduction Program

Neuropsychological Consultation as Part of Pediatric Diabetes Care: Does it Improve Glycemic Control and Family Functioning?

Marcaine Post-Operative Pain Study

Mindfulness for Alcohol Abusing Offenders